Primary cutaneous malignant melanoma and its precursor lesions: Diagnostic and therapeutic overview

Journal of the American Academy of Dermatology

Volumn 45, Issue 2, 2001, Pages 260-276

  Kanzler, Matthew H ^a   Mraz Gernhard, Serena ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CONGENITAL NEVUS; DIAGNOSTIC TEST; DYSPLASTIC NEVUS; EPILUMINESCENCE MICROSCOPY; EVIDENCE BASED MEDICINE; LYMPH NODE DISSECTION; MELANOMA; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE;

EID: 0034898584     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.116239     Document Type: Article

References (115)

1. Risk factors for cutaneous melanoma
2. Melanoma, melanocyte nevi and other melanoma risk factors in children
3. Number of melanocytic nevi as a major risk factor for malignant melanoma
4. Benign melanocyte nevi as a risk factor for malignant melanoma
5. Risks of cutaneous melanoma in relation to the numbers, types, and sites of naevi: A case-control study
6. Clinically recognized dysplastic nevi: A central risk factor for cutaneous melanoma
7. Anatomic distribution of acquired melanocyte nevi in white children
8. Malignant melanoma in southern Germany: Different predictive value of risk factors for melanoma subtypes
9. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma
10. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma
11. Acquired melanocytic nevi and melanoma: The dysplastic nevis syndrome
12. Nevomelanocytic proliferations in association with cutaneous malignant melanoma: A multivariate analysis
13. Origin of familial malignant melanomas from heritable melanocytic lesions: The B-K mole syndrome
14. Precursor naevi in cutaneous malignant melanoma: A proposed nomenclature
15. Diagnosis and treatment of early melanoma
16. Prevalence of dysplastic nevi in a community practice
17. The prospective diagnosis of malignant melanoma in a population at high risk: Hereditary melanoma and the dysplastic nevus syndrome
18. Prediction of historical melanocytic dysplasia from clinical observation
19. Histologic atypia in clinically benign nevi
20. The dysplastic melanoma nevus: A prevalent lesion that correlates poorly with clinical phenotype
21. Correlation of clinical pigmentary characteristics with histopathologically-confirmed dysplastic nevi in nonfamilial melanoma patients: Studies of melanocytic nevi IX
22. Consensus conference. Precursors to malignant melanoma
23. Small congenital nevocellular nevi and the risk of cutaneous melanoma
24. Pigmented lesions in newborn infants
25. Congenital nevocytic nevi in malignant melanoma
26. Congenital nevi ≤10 cm as precursors to melanoma
27. Non-epidermal origin of cutaneous melanoma in a small congenital nevus
28. Malignant melanoma arising intradermally in a small congenital nevus of an adult
29. The risk of melanoma in patients with congenital nevi: A cohort study
30. Risk of melanoma in medium-sized congenital melanocytic nevi: A follow-up study
31. Cutaneous melanoma risk and phenotype changes in large congenital nevi: A follow-up study of 46 patients
32. Neuroextradermal neoplasms arising in congenital nevi
33. The risk of malignancy in large congenital nevi
34. Non-epidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus
35. Malignant melanoma in children: A review
36. The histogenesis and biologic behavior of primary human malignant melanoma of the skin
37. Prognostic factors in the treatment of cutaneous melanoma
38. Thin level IV malignant melanoma: A subset in which level is the major prognostic indicator
39. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness
40. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system
41. A prognostic model for predicting 10-year survival in patients with primary melanoma
42. Malignant melanoma of the skin: The association of tumor depth and type, and patient sex, age, and site with survival
43. Prognostic models in melanoma
44. Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant-melanoma
45. The pathology of melanoma as a basis for prognostic models: The UCSF experience
46. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma
47. The role for close follow-up of melanoma patients with AJCC stages I-III: A preliminary analysis
48. LDH and melanoma
49. Role of computed tomography in the staging of patients with local-regional metastases of melanoma
50. Diagnosis of metastic melanoma at distant sites
51. Use of chest radiographs in the initial evaluation of patients with localized melanoma
52. Impact of follow-up teaching on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial
53. Role of computed tomography in the staging of primary melanoma
54. Pediatrics value of staging: Investigations in patients with clinical stage I malignant melanoma
55. Radionucleotide photoscanning: Usefulness in preoperative evaluation of melanoma patients
56. Scintiscans in the evaluation of patients with malignant melanomas
57. Radionuclide scans not indicated for clinical stage I melanoma
58. Preoperative nuclear scans in patients with melanoma
59. Value of liver scintigraphy in pretreatment staging and in follow-up of patients with malignant melanoma
60. The multidisciplinary melanoma clinic: A cost outcomes analysis of specialty care
61. Early detection of melanoma metastasis using fludeoxyglucose F 18 positron emission tomography
62. Malignant melanoma staging using whole body positron emission tomography
63. Positron emission tomography in the detection and management of metastatic melanoma
64. Cutaneous melanoma: Patient surveillance and tumor progression
65. Intervention strategy to prevent lethal cutaneous melanoma: Use of dermatologic photography to aid surveillance of high-risk persons
66. Clinicopathological features of small diameter malignant melanoma
67. Small-diameter malignant melanoma: A common diagnosis in New South Wales, Australia
68. "Small" melanomas: Relation of prognostic variables to diameter of primary superficial spreading melanomas
69. The natural history of dysplastic nevi: A case history illustrating their evolution
70. Natural history of dysplastic nevi
71. Photographic utilization in dermatology clinics in the United States: A survey of university-based dermatology residency programs
72. Total-body photographs of dysplastic nevi
73. Photography for the early diagnosis of malignant melanoma in patients with atypical moles
74. Clinical characteristics of malignant melanomas developing in persons with dysplastic nevi
75. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance
76. Reevaluation of the ABCD rule for epiluminescence microscopy
77. The ABCD rule of dermatoscopy: High prospective value in the diagnosis of doubtful melanocytic skin lesions
78. Epiluminescence microscopy of small pigmented skin lesions: Short-term formal training improves diagnostic performance of dermatologists
79. Differential diagnosis of pigmented skin lesions
80. Terminology in surface microscopy
81. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions: Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis
82. The morphologic criteria of the pseudopod in surface microscopy
83. Epiluminescence microscopy: Criteria of cutaneous melanoma progression
84. Morphologic changes of pigmented skin lesions: A useful extension of the ABCD rule for dermatoscopy
85. Frequency and morphologic characteristics of invasive melanomas lacking specific surface microscopic features
86. The misdiagnosis of malignant melanoma
87. NIH Consensus Development Panel on Early Melanoma: Diagnosis and treatment of early melanoma
88. Cutaneous cancer and malignant melanoma
89. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. II. Definitive surgery for malignant melanoma
90. The pathology of melanocytic growth in relation to their operative treatment, lecture 1
91. Thin stage I primary cutaneous malignant melanoma: Comparison of excision with margins of 1 or 3 cm
92. Narrow excision (1 cm margins): A safe procedure for thin cutaneous melanoma
93. Prognosis for recurrent stage I malignant melanoma
94. Efficacy of 2 cm. surgical margins for intermediate-thickness melanomas (1-4 mm): Results of a multiinstitutional randomized surgical trial
95. Surgical margins for excision of primary cutaneous melanomas
96. A centimeter here, a centimeter there: Does it matter?
97. Early stage melanoma: Lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe
98. Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma
99. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma
100. Antigen localization and migration in immunity and tolerance
101. Inefficacy of immediate node dissection in stage I melanoma of the limbs
102. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremity
103. Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study
104. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
105. Technical details of intra-operative lymphatic mapping for early stage melanoma
106. Minimal-access surgery for staging of malignant melanoma
107. The orderly progression of melanoma nodal metastases
108. Invited commentary
109. Optimal selective sentinel node dissection in primary malignant melanoma
110. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy
111. Altered lymphatic drainage following lymphadenectomy
112. Clinical significance of melanoma micrometastasis to sentinel lymph nodes and other high risk factors
113. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
114. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190